New Delhi: Hetero has announced the export launch of its generic semaglutide portfolio, marking a significant step toward expanding access to GLP-1 therapies for the treatment of type 2 diabetes and obesity.The launch represents the beginning of a strategic, multi-year global rollout across more than 75 countries, as part of Hetero’s focus on improving access to advanced cardio-metabolic therapies. Initial launches are underway in Africa, Asia, and the Middle East, with further rollouts planned, subject to regulatory approvals.The injectable semaglutide therapies will be marketed under the brand names Truglyx, Rolmodl and Moto G across markets.Also Read: Hetero appoints Kshitiz Gadodia to Global Team as President – Finance & AccountsHetero is currently awaiting approval from India’s national regulator, CDSCO, following the completion of clinical trials in type 2 diabetes and obesity. Launch in India is anticipated post regulatory approvals.Commenting on the launch, Dr. Vamsi Krishna Bandi, Managing Director, Hetero, said “With this launch, our goal is to offer a high-quality, affordable generic semaglutide to patients across emerging markets. We have developed a single, global-quality product platform, reflecting our capabilities in advanced product development and the manufacturing of complex generics. Leveraging our established commercial networks across Asia, the Middle East, Africa, and Latin America, we remain focused on expanding access to high-quality therapies in the diabetes and metabolic care space, while ensuring a consistent global supply.”The portfolio will be available in multi-dose disposable pen devices designed in line with innovator formats, and across multiple dose strengths including 0.25 mg, 0.5 mg, 1 mg, 2 mg,1.7 mg and 2.4 mg, supporting both type 2 diabetes and weight management, and enabling flexible, patient-centric dosing.Also Read:Cipla, Hetero win bid to supply widely prescribed diabetes drug in ChinaHetero is a global pharmaceutical company focused on the development, manufacturing and commercialization of Active Pharmaceutical Ingredients (APIs) and generic formulations.Headquartered in Hyderabad, India, Hetero operates in more than 145 countries and is a trusted partner to multinational pharmaceutical companies and global procurement agencies. With over three decades of experience and a workforce of more than 30,000 professionals, the company is committed to improving access to affordable, high-quality medicines worldwide.